source
- Amgen drops early-stage obesity drug candidate AMG-513Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…
- Lisata Therapeutics cuts 72% of staff after merger with Kuva falls through and files lawsuitLisata Therapeutics announced it is cutting about 72% of its full‑time workforce after a planned merger with Kuva Labs collapsed. The company had 21 full‑time employees at the end of 2025, so roug…